Minerva neurosciences Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Minerva neurosciences Contact Number

Minerva Neurosciences

7 hours ago Minervaneurosciences.com Get All

(617) 600-7376

Contact; Nasdaq NERV. Clinical Expertise and Patient Focus. Our skills in clinical development define our core expertise in central nervous system disorders. We are focused on designing innovative trials with clinical endpoints directly related to patient benefit, and we seek to recruit patients who will benefit from treatment with our product

1. 47 Hulfish St Ste 310, Princeton, NJ 08542 · (617) 600-7376DIRECTIONSWEBSITE

Website: https://www.minervaneurosciences.com/

Category: Contact NumberShow more

Minerva Neuroscience Crunchbase Company Profile & …

Just Now Crunchbase.com Get All

Phone Number (908)683-8300. Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus.

Founded: 2007

Website: https://www.crunchbase.com/organization/minerva-neuroscience

Category: Contact NumberShow more

Minerva Neurosciences, Inc. Company Profile Waltham, …

9 hours ago Dnb.com Get All

Find company research, competitor information, contact details & financial data for Minerva Neurosciences, Inc. of Waltham, MA. Get the latest business insights from Dun & Bradstreet.

Website: https://www.dnb.com/business-directory/company-profiles.minerva_neurosciences_inc.17b38ff807679d2b124a98b553738a3c.html

Category: Contact NumberShow more

Minerva Neurosciences Inc ZIP 02451, NAICS 621511

4 hours ago Siccode.com Get All

"Minerva Neurosciences Inc" of Waltham, MA 02451 operates primarily in SIC Code 8071 - Medical Laboratories and NAICS Code 621511 - Medical Laboratories. Minerva Neurosciences Inc is a small-sized business with low revenue, that is well-established in its industry.

Website: https://siccode.com/business/minerva-neurosciences-inc

Category: Contact NumberShow more

Minerva Neurosciences Company Profile Office …

8 hours ago Craft.co Get All

Minerva Neurosciences has 13 employees at their 1 location and $41.18 M in annual revenue in FY 2020. See insights on Minerva Neurosciences including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Founded: 2007
Type: Public
Net income (Q3, 2020): (8.1m)
Website: minervaneurosciences.com

Website: https://craft.co/minerva-neurosciences

Category: Contact NumberShow more

Leadership • Minerva Neurosciences

7 hours ago Minervaneurosciences.com Get All

Executive Management Team. Dr. Remy Luthringer was named Executive Chairman of the Board on February 5, 2018 and has served as the Chief Executive Officer of Minerva Neurosciences, Inc. since November 2014. He has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system.

Website: https://www.minervaneurosciences.com/about-us/leadership/

Category: Contact NumberShow more

Contact – Minerva Foundation Institute for Medical …

7 hours ago Minervainstitute.wordpress.com Get All

358 50 4487

POSTAL AND VISITING ADDRESS BIOMEDICUM Helsinki 2UTukholmankatu 800290 HELSINKI, FinlandTel. +358 50 4487771VAT number: FI01272083 Minerva Foundation contact information. DIRECTOR OF THE INSTITUTE Professor Vesa OlkkonenTel: +358 50 4112297Email: [email protected] LABORATORY CHIEF Cia OlssonTel: +358 50 4487771Email: …

Website: https://minervainstitute.wordpress.com/contact/

Category: Contact SupportShow more

NERV Minerva Neurosciences Inc • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Get All

WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2021. Roluperidone Update . Following the completion of the …

Website: https://www.biopharmcatalyst.com/company/nerv

Category: Contact NumberShow more

Home Minerva Surgical, Inc

8 hours ago Minervasurgical.com Get All

Experience Minerva ES The all-in-one Symphion System is designed to transform the way you see and remove uterine fibroids and polyps. Breakthrough fluid management, direct intrauterine pressure monitoring and bladeless resection work in concert to improve safety and ease of use.

Website: https://minervasurgical.com/

Category: Home PhoneShow more

Minerva Neurosciences Number of Employees 20132021 NERV

8 hours ago Macrotrends.net Get All

Minerva Neurosciences number of employees from 2013 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

Website: https://www.macrotrends.net/stocks/charts/NERV/minerva-neurosciences/number-of-employees

Category: Contact NumberShow more

FORM D SEC

4 hours ago Sec.gov Get All

617-600-7373

Minerva Neurosciences, Inc. Street Address 1 Street Address 2; 1601 TRAPELO ROAD: SUITE 284: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; WALTHAM: MASSACHUSETTS: 02451: 617-600-7373

Website: https://www.sec.gov/Archives/edgar/data/1598646/000159864616000004/xslFormDX01/primary_doc.xml

Category: Contact NumberShow more

Minerva Neurosciences to Report First Quarter 2021

9 hours ago Apnews.com Get All

(617) 600-7376

Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com. Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376

Website: https://apnews.com/press-release/globe-newswire/business-65473c912d2101ba83d707c6bf06f219

Category: Contact NumberShow more

Pharmacokinetic Study of MIN101 in Healthy Subjects

7 hours ago Clinicaltrials.gov Get All

02 2014-0016

Minerva Neurosciences: ClinicalTrials.gov Identifier: NCT02232529 Other Study ID Numbers: MIN-101C02 2014-001613-53 ( EudraCT Number ) First Posted: September 5, 2014 Key Record Dates: Last Update Posted: February 24, 2015 Last Verified: February 2015

Website: https://clinicaltrials.gov/ct2/show/NCT02232529

Category: Contact NumberShow more

Minerva Neurosciences, Inc: Minerva Neurosciences and

9 hours ago Bloomberg.com Get All

Minerva Neurosciences is entitled to a mid-single digit royalty on worldwide net sales of seltorexant. all of the market data included in this document involves a number of assumptions and

Website: https://www.bloomberg.com/press-releases/2021-01-19/minerva-neurosciences-inc-minerva-neurosciences-and-royalty-pharma-announce-sale-of-seltorexant-royalty-for-up-to-155

Category: Contact NumberShow more

Minerva Neurosciences Inc. (NERV):Sell today, is the

6 hours ago Baxterreport.com Get All

The total number of common shares currently owned by the public is 42.72 million. NERV does have institutional investors; and they hold 64.10% of the stock. Minerva Neurosciences Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Website: https://baxterreport.com/2021/09/15/minerva-neurosciences-inc-nervsell-today-is-the-recommendation-of-the-stocks-medium-term-indicators/

Category: Contact NumberShow more

Minerva Neurosciences, Inc Common Stock (NERV

3 hours ago Nasdaq.com Get All

Minerva Neurosciences, Inc Common Stock (NERV) including the number of shares held by those institutions in a firm, along with recent purchases and sales information. Contact

Website: https://www.nasdaq.com/market-activity/stocks/nerv/institutional-holdings

Category: Contact NumberShow more

MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE …

4 hours ago Sec.gov Get All

FOR IMMEDIATE RELEASE . MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE SALE OF . SELTOREXANT ROYALTY FOR UP TO $155 MILLION . Waltham, MA and New York, NY, January 19, 2021 – Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for …

Website: https://www.sec.gov/Archives/edgar/data/1598646/000119312521010858/d945121dex991.htm

Category: Contact NumberShow more

What Type Of Shareholders Own The Most Number of Minerva

9 hours ago Finance.yahoo.com Get All

Minerva Neurosciences is not a large company by global standards. It has a market capitalization of US$125m, which means it wouldn't have the attention of many institutional investors.

Website: https://finance.yahoo.com/news/type-shareholders-own-most-number-092032178.html

Category: Contact NumberShow more

SEC Filing MINERVA NEUROSCIENCES, INC

Just Now Ir.minervaneurosciences.com Get All

517 26-0784

Minerva Neurosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36517 26-0784194 (State or other jurisdiction. of incorporation) (Commission. File Number

Website: http://ir.minervaneurosciences.com/node/10481/html

Category: Contact NumberShow more

Jobs with Minerva Neurosciences, Inc. BioSpace

8 hours ago Biospace.com Get All

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021Management to host conference call. 7/26/2021. Minerva Neurosciences, Inc. today announced that it will release financial results and business updates for the second quarter of 2021 on Monday, August 2, 2021.

Website: https://www.biospace.com/employer/544440/minerva-neurosciences-inc-/

Category: Contact NumberShow more

Minerva Neurosciences to Report Second Quarter 2021

8 hours ago Ir.minervaneurosciences.com Get All

Management to host conference call. WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of …

Website: http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-report-second-quarter-2021-financial

Category: Contact NumberShow more

Minerva Neurosciences to Report Second Quarter 2021

2 hours ago Ca.finance.yahoo.com Get All

(617) 600-7376

Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com. Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376

Website: https://ca.finance.yahoo.com/news/minerva-neurosciences-report-second-quarter-123000406.html

Category: Contact NumberShow more

Minerva Neurosciences to Report Third Quarter 2020

5 hours ago Biospace.com Get All

(617) 600-7376

Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com. Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376

Website: https://www.biospace.com/article/releases/minerva-neurosciences-to-report-third-quarter-2020-financial-results-and-business-updates-on-november-2-2020management-to-host-conference-call/

Category: Contact NumberShow more

Minerva Neurosciences to Report Third Quarter 2020

8 hours ago Finance.yahoo.com Get All

For more information, please visit www.minervaneurosciences.com.Contact:William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. …

Website: https://finance.yahoo.com/news/minerva-neurosciences-report-third-quarter-123000412.html

Category: Contact NumberShow more

Minerva Neurosciences to Report Third Quarter 2020

3 hours ago Ca.news.yahoo.com Get All

(617) 600-7376

Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.Contact:William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376

Website: https://ca.news.yahoo.com/minerva-neurosciences-report-third-quarter-123000412.html

Category: Contact NumberShow more

Minerva Neurosciences to Report Second Quarter 2021

3 hours ago Globenewswire.com Get All

(765) 507-2618

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 or (765) 507-2618 (international) and referring to conference ID number

Website: https://www.globenewswire.com/news-release/2021/07/26/2268590/32445/en/Minerva-Neurosciences-to-Report-Second-Quarter-2021-Financial-Results-and-Business-Updates-on-August-2-2021.html

Category: Contact NumberShow more

Minerva Neurosciences, Inc: Minerva Neurosciences Reports

6 hours ago Bloomberg.com Get All

Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support

Website: https://www.bloomberg.com/press-releases/2020-08-03/minerva-neurosciences-inc-minerva-neurosciences-reports-second-quarter-2020-financial-results-and-business-updates

Category: Contact NumberShow more

Minerva Neurosciences Reports First Quarter 2021 Financial

2 hours ago Nz.finance.yahoo.com Get All

Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psychotic relapses over one year Pivotal bioequivalence study initiated WALTHAM, Mass., May 12, 2021 …

Website: https://nz.finance.yahoo.com/news/minerva-neurosciences-reports-first-quarter-113000137.html

Category: Contact NumberShow more

MINERVA NEUROSCIENCES, INC. : NERV Stock Price

7 hours ago Marketscreener.com Get All

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases.

Website: https://www.marketscreener.com/quote/stock/MINERVA-NEUROSCIENCES-IN-16772158/

Category: Contact NumberShow more

NERV.OQ Minerva Neurosciences Inc Key Developments Reuters

8 hours ago Reuters.com Get All

Minerva Neurosciences Posts Q1 Loss Per Share $0.21. May 12 (Reuters) - Minerva Neurosciences Inc <NERV.O>::MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND BUSINESS UPDATES

Website: https://www.reuters.com/companies/NERV.OQ/key-developments

Category: Contact NumberShow more

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on

4 hours ago Seekingalpha.com Get All

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q2 2021 Results Conference Call August 2, 2021 8:30 AM ET Company Participants William Boni - …

Website: https://seekingalpha.com/article/4444063-minerva-neurosciences-inc-nerv-ceo-remy-luthringer-on-q2-2021-results-earnings-call

Category: Contact NumberShow more

NERV Minerva Neurosciences Inc. Stock Price & News WSJ

3 hours ago Wsj.com Get All

News Minerva Neurosciences Inc.NERV. No news for in the past two years. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price

Website: https://www.wsj.com/market-data/quotes/NERV

Category: Contact NumberShow more

Minerva Neurosciences to Report Second Quarter 2020

2 hours ago Ca.finance.yahoo.com Get All

(617) 600-7376

Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.Contact:William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376

Website: https://ca.finance.yahoo.com/news/minerva-neurosciences-report-second-quarter-120000307.html

Category: Contact NumberShow more

Minerva Neurosciences Reports First Quarter 2021 Financial

6 hours ago Nasdaq.com Get All

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities. To participate, please dial (877

Website: https://www.nasdaq.com/press-release/minerva-neurosciences-reports-first-quarter-2021-financial-results-and-business

Category: Contact NumberShow more

Minerva Neurosciences Announces the Results of the Phase 3

6 hours ago Globenewswire.com Get All

About Minerva Neurosciences Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in …

Website: https://www.globenewswire.com/news-release/2021/05/11/2227656/32445/en/Minerva-Neurosciences-Announces-the-Results-of-the-Phase-3-Trial-of-Roluperidone-for-the-Treatment-of-Negative-Symptoms-of-Schizophrenia-Following-the-Completion-of-the-40-Week-Ope.html

Category: Contact NumberShow more

NERV News Today (Minerva Neurosciences) MarketBeat

1 hours ago Marketbeat.com Get All

Minerva Neurosciences (NERV) Enters Overbought Territory finance.yahoo.com - May 19 at 7:19 AM: Minerva Neurosciences, Inc : Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates markets.businessinsider.com - May 14 at 9:21 AM: Why Minerva Neurosciences' Stock Is Trading Higher Today msn.com - May 12 at 6:17 PM

Website: https://www.marketbeat.com/stocks/NASDAQ/NERV/news/

Category: Contact NumberShow more

Minerva Neurosciences Inc. (NASDAQ: NERV) Could Pass $10

Just Now Stocksregister.com Get All

Minerva Neurosciences Inc., which has a market valuation of $76.90 million, is expected to release its quarterly earnings report Nov 01, 2021 – Nov 05, 2021. Analysts tracking NERV have forecast the quarterly EPS to shrink by -0.17 per share this quarter, while the same analysts predict the annual EPS to hit -$0.9 for the year 2021 and up to

Website: https://stocksregister.com/2021/08/23/minerva-neurosciences-inc-nasdaq-nerv-could-pass-10-00-in-one-year-stock-forecast/

Category: Contact NumberShow more

Should You Sell Minerva Neurosciences Inc (NERV) Stock

1 hours ago Investorsobserver.com Get All

Minerva Neurosciences Inc has a Long-Term Technical rank of 2. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 98% of the market scoring higher. In the Biotechnology industry which is number 137 by this metric, NERV ranks better than 7% of stocks. Important Dates for Investors in NERV:

Website: https://www.investorsobserver.com/news/stock-update/should-you-sell-minerva-neurosciences-inc-nerv-stock-thursday-morning

Category: Contact NumberShow more

NERV Stock Price Minerva Neurosciences Inc. Stock Quote

8 hours ago Marketwatch.com Get All

Minerva Neurosciences's stock nearly triples premarket after positive trial results May. 26, 2016 at 8:48 a.m. ET by Tomi Kilgore Micron Tech shares fall after revenue miss

Website: https://www.marketwatch.com/investing/Stock/NERV

Category: Contact NumberShow more

Minerva Neurosciences Inc (NERV) is up 5.98% Friday In

1 hours ago Investorsobserver.com Get All

Minerva Neurosciences Inc has a Long-Term Technical rank of 5. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 95% of the market scoring higher. In the Biotechnology industry which is number 130 by this metric, NERV ranks better than 11% of stocks. Important Dates for Investors in NERV:

Website: https://www.investorsobserver.com/news/stock-update/minerva-neurosciences-inc-nerv-is-up-5-98-friday-in-premarket-trading

Category: Contact NumberShow more

Minerva Neurosciences Inc. (NERV): The long term

2 hours ago Baxterreport.com Get All

The total number of common shares currently owned by the public is 42.72 million. NERV does have institutional investors; and they hold 64.10% of the stock. Minerva Neurosciences Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 0 new insider purchases involving 0 shares.

Website: https://baxterreport.com/2021/09/21/minerva-neurosciences-inc-nerv-the-long-term-indicators-on-the-stock-say-sell-today-2/

Category: Contact NumberShow more

Minerva Neurosciences Inc. (NASDAQ: NERV) Down 3.53%

2 hours ago Stocksregister.com Get All

According to the data, the short interest in Minerva Neurosciences Inc. (NERV) stood at 7.83% of shares outstanding as of May 27, 2021; the number of short shares registered in Apr 29, 2021 reached 2.76 million. The stock has fallen by -21.37% since the beginning of the year, thereby showing the potential of a further growth.

Website: https://stocksregister.com/2021/09/24/minerva-neurosciences-inc-nasdaq-nerv-down-3-53-what-analysts-predict-now/

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is minerva neurosciences inc?

Minerva Neurosciences Inc. Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301.

Is the options market predicting a spike in minerva neurosciences nerv?

Is the Options Market Predicting a Spike in Minerva Neurosciences (NERV) Stock? Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't?

How does minerva surgical all in one symphion system work?

The all-in-one Symphion System is designed to transform the way you see and remove uterine fibroids and polyps. Breakthrough fluid management, direct intrauterine pressure monitoring and bladeless resection work in concert to improve safety and ease of use. One system, built for efficiency and safety.

How does minerva surgical target the root cause of aub?

Target the root cause of AUB with devices that deliver unmatched efficiency and results. Tap into on-demand tech support, training and education for practitioners and all staff. Our sole focus on device enabled innovations in Women’s Health means no aspect of your experience escapes our scrutiny.

Brand New Updated

Popular Brands

Merck
Man
Maaden
Mcx
Midea
Metro
Mapfre